• FDA acts on CAR T-cell therapy, other top stories in hematology/oncology

    10 monthes ago - By Healio

    The FDA recently granted its regenerative medicine advanced therapy designation to a chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory multiple myeloma - an indication that the therapy, called CT053, can address an unmet medical need for patients with the disease.
    Read a summary of the FDA's decision and all of last's week's top stories in hematology/oncology.
    FDA grants CAR T-cell therapy regenerative medicine advanced therapy designation for multiple myeloma
    The FDA has granted its regenerative medicine advanced therapy
    Read more ...